Jiangxi Bio (6915.HK) climbed 8% during regular trading to HK$4.890.
The surge followed news that a subsidiary recently received approval for veterinary tetanus antitoxin, serving as the primary catalyst for the stock's movement.
Jiangxi Bio (6915.HK) climbed 8% during regular trading to HK$4.890.
The surge followed news that a subsidiary recently received approval for veterinary tetanus antitoxin, serving as the primary catalyst for the stock's movement.